Black Titan (NASDAQ:BTTC) vs. Doximity (NYSE:DOCS) Financial Contrast

Black Titan (NASDAQ:BTTC) and Doximity (NYSE:DOCS) are both services companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Profitability

This table compares Black Titan and Doximity’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Black Titan	N/A	N/A	N/A
Doximity	37.54%	23.84%	20.42%

Risk and Volatility

Black Titan has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500. Comparatively, Doximity has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500.

Institutional and Insider Ownership

87.2% of Doximity shares are owned by institutional investors. 53.7% of Black Titan shares are owned by company insiders. Comparatively, 31.3% of Doximity shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Black Titan and Doximity”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Titan	$180,000.00	77.70	-$4.71 million	($2.95)	-0.47
Doximity	$570.40 million	7.84	$223.18 million	$1.20	20.18

Doximity has higher revenue and earnings than Black Titan. Black Titan is trading at a lower price-to-earnings ratio than Doximity, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations for Black Titan and Doximity, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Titan	1	0	0	0	1.00
Doximity	1	7	12	2	2.68

Doximity has a consensus target price of $41.26, indicating a potential upside of 70.36%. Given Doximity’s stronger consensus rating and higher probable upside, analysts clearly believe Doximity is more favorable than Black Titan.

Summary

Doximity beats Black Titan on 13 of the 15 factors compared between the two stocks.

About Black Titan

Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.

About Doximity

Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company’s cloud-based platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers. It primarily serves pharmaceutical companies and health systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.